aDepartment of Radiation Oncology, University of Toronto bDepartment of Radiation Oncology, Princess Margaret Cancer Centre, Toronto.
Curr Opin Oncol. 2014 Jan;26(1):45-50. doi: 10.1097/CCO.0000000000000027.
The role of external beam radiation therapy (EBRT) in the management of thyroid cancer is not clearly defined. In the absence of randomized studies, the review aims to identify any recent literature that helps define the role.
In differentiated thyroid cancer, single institutional studies report durable locoregional disease control in patients considered to be at high risk of local relapse after EBRT and recent guidelines are consistent in their recommendations. In medullary thyroid cancer, the evidence is more limited but again there is benefit in selected cases. In anaplastic thyroid cancer, multimodality therapy is superior to surgery alone in achieving local control and possibly survival but the benefit must be weighed against the toxicity. Newer radiation techniques may help reduce toxicity.
Although surgery is the main treatment for thyroid carcinoma, EBRT has a role in the adjuvant setting following surgery in high-risk patients and in unresectable cancer. Advances in the delivery of external beam radiotherapy, including intensity-modulated radiotherapy reduces toxicity.
外照射放疗(EBRT)在甲状腺癌治疗中的作用尚未明确。由于缺乏随机研究,本综述旨在确定任何有助于明确该作用的最新文献。
在分化型甲状腺癌中,单机构研究报告称,在 EBRT 后局部复发风险高的患者中,EBRT 可持久控制局部疾病,且近期指南的推荐意见一致。在甲状腺髓样癌中,证据更为有限,但在某些情况下仍有益处。在间变性甲状腺癌中,与单纯手术相比,多模式治疗可更好地实现局部控制和可能的生存,但必须权衡其毒性。新的放射技术可能有助于降低毒性。
尽管手术是甲状腺癌的主要治疗方法,但 EBRT 在高危患者手术后的辅助治疗和不可切除的癌症中有一定作用。外照射放疗的应用进展,包括调强放疗,降低了毒性。